title: Effect of growth hormone treatment on hyperinsulinemia associated with Turner syndrome.
abstract: To determine whether the insulin resistance in patients with Turner syndrome, which may be exaggerated by treatment with human growth hormone, leads to excessive insulin secretion, we applied the hyperglycemic glucose-clamp technique to produce a standard hyperglycemic stimulus (6.9 mmol/L, or 125 mg/dl, greater than fasting plasma glucose level for 120 minutes) in seven patients with Turner syndrome and in seven healthy children. These studies were repeated in the patients after 6 to 12 months of therapy with growth hormone. Fasting plasma levels of insulin were comparable in control subjects and patients before therapy but increased significantly in the patients after 6 to 12 months of treatment with growth hormone. Despite identical glucose increments in the two groups during the glucose-clamp procedure, both first- and second-phase insulin responses were significantly greater in the patients than in the control subjects. Moreover, the hyperinsulinemic responses to glucose were markedly exaggerated in the patients after their treatment with growth hormone, reaching values (first phase 474 +/- 100 pmol and second phase 826 +/- 100 pmol; p less than 0.02 vs pretreatment values) that were almost threefold greater than those in control subjects (p less than 0.001). Nevertheless, the rate of insulin-stimulated glucose metabolism during the last 60 minutes of the clamp procedure was similar in all three groups of studies. Glycosylated hemoglobin, total cholesterol level, and blood pressure remained normal in patients after therapy with growth hormone. We conclude that glucose-stimulated insulin response is increased in patients with Turner syndrome and that these alterations are further exaggerated by treatment with growth hormone. These hyperinsulinemic responses appear to compensate for reductions in insulin sensitivity.
authors.affiliation: Department of Pediatrics, Yale University School of Medicine, New Haven, Connecticut 06510.
authors.forename: S
authors.initials: S
authors.lastname: Caprio
authors.forename: S D
authors.initials: SD
authors.lastname: Boulware
authors.forename: M
authors.initials: M
authors.lastname: Press
authors.forename: R S
authors.initials: RS
authors.lastname: Sherwin
authors.forename: K
authors.initials: K
authors.lastname: Rubin
authors.forename: T O
authors.initials: TO
authors.lastname: Carpenter
authors.forename: G
authors.initials: G
authors.lastname: Plewe
authors.forename: W V
authors.initials: WV
authors.lastname: Tamborlane
mesh_terms: D000293:Adolescent; D002096:C-Peptide / Q000097:blood; D002648:Child; D002784:Cholesterol / Q000097:blood; D005260:Female; D015309:Glucose Clamp Technique; D006442:Glycated Hemoglobin / Q000032:analysis; D013006:Growth Hormone / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007328:Insulin / Q000097:blood*; D007333:Insulin Resistance; D014424:Turner Syndrome / Q000188:drug therapy* / Q000378:metabolism
chemical_list: D002096:C-Peptide; D002784:Cholesterol; D006442:Glycated Hemoglobin; D013006:Growth Hormone; D007328:Insulin